Friday 6 November 2026 Export TAK’s income statement to Excel — free account

Takeda Pharmaceutical Co.

TAK Healthcare Drug Manufacturers Specialty & Generic

Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.

Revenue: +1.71%
EPS: −4.35%
Free cash flow: +54.9%
Total debt: −7.28%

Quarter to September 2026, against a year earlier

21.25 0.19 +0.90%

Follow TAK

Alert me

Market cap: $67.7B
P/E: 32.0×
Fwd P/E: —
Dividend yield: 1.45%
F-score: 4/9
Altman Z: 1.03
Beneish M: −2.65
Dividend safety: 25/100

Overview

Takeda Pharmaceutical Co. (TAK) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Takeda Pharmaceutical Co. (TAK) trades at a P/E ratio of 32.0×. Over the past ten years it has ranged from 0.0× (June 2017) to 150× (May 2020); the current reading is higher than 62% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 20.5× and above the Healthcare sector median of 25.2×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TAK/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Takeda Pharmaceutical Co. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TAK/metrics/pe-ratio">Takeda Pharmaceutical Co. (TAK) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2026	27.5×	(44.82%)
FY2025	49.7×	16.06%
FY2024	42.9×	100.28%
FY2023	21.4×	(1.84%)
FY2022	21.8×	36.12%
FY2021	16.0×	(86.25%)
FY2020	117×	1,094.01%
FY2019	9.8×	(85.20%)
FY2018	65.9×	—
FY2017	0.0×	—

Period	P/E ratio	Change
Jun 2026	24.1×	5.25%
Jun 2025	22.9×	(47.31%)
Jun 2024	43.5×	1.46%
Mar 2024	42.9×	23.85%
25 more quarters	Free account

Against its own ten years

Low 0.0× High 150×

Ten-year median 23.4×

Current reading's percentile 54

Company	P/E ratio
VTRS Viatris Inc. compare	n/m
ELAN Elanco Animal Health Incorporated compare	n/m
ZTS Zoetis Inc. compare	13.4×
UTHR United Therapeutics Corporation compare	19.7×
HLN Haleon PLC Sponsored ADR compare	20.5×
NBIX Neurocrine Biosciences, Inc. compare	23.0×
TAK Takeda Pharmaceutical Co.	32.0×
RDY Dr. Reddy's Laboratories Ltd compare	44.4×
TEVA Teva Pharmaceutical Industries Ltd. compare	92.6×
Drug Manufacturers Specialty & Generic industry median	20.5×
Healthcare sector median	25.2×
Market median	17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Takeda Pharmaceutical Co. (TAK) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on TAK

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on TAK

Stockrow Weekly